New combo therapy aims to keep aggressive blood cancer at bay after transplant
NCT ID NCT05776979
Summary
This study is testing whether adding a drug called isatuximab to the standard maintenance drug lenalidomide can better control high-risk multiple myeloma after a patient's own stem cell transplant. It will involve about 61 adults who have this aggressive form of the blood cancer and have already had a transplant. The main goal is to see if this combination can keep the cancer from progressing longer than current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.